My main research interest is in coupling cognitive neuroscience (including experimental psychology, computational modeling and neuroimaging) and pharmacological challenges in patients as well as in normal volunteers. I’m also interested in better understanding how inflammation could cause or at least worsen mental diseases, using both clinical and preclinical studies. In both fields, i.e. cognitive neuroscience and inflammation related diseases, pharmacological challenges (psychotomimetic drugs/antipsychotics, depressogenic drugs/antidepressants, anxiolytics, mood regulators) are considered as a way to better characterize pathophysiology and to pave the way for innovative treatment strategies.
Click to view graph
Connections
Click to view timeline
Timeline
Projects
CV
Current position
Head of the 15th department of psychiatry since 2011, Sainte Anne hospital – Paris Descartes University (15th district of Paris, 9 wards, 200 beds, 6 outpatients facilities, 12 000 patients a year)
Full professor since 2012 in the Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Sainte Anne hospital – Paris Descartes University.
Training
Post-doctoral position: research associate (2009-2010), Brain Mapping Unit, Cambridge University, Prof. Fletcher
2007 : PhD in neurosciences. Louis Forest’award from the Chancellerie des Universités de Paris
Direction : Docteur Lionel Naccache
Jury : Professeur Stanislas Dehaene, Professeur Francis Eustache, Professeur Philippe Fossati, Professeur Marie-Odile Krebs, Docteur Lionel Naccache, Docteur Catherine Tallon-Baudry, Professeur Patrik Vuilleumier (Genève)
2004 : MD diploma. Pierre Robin’s award from the Chancellerie des Universités de Paris
2000-2007 : residency and training in psychiatry in Paris
1996-2000 : graduated from the Ecole Normale Supérieure de la rue d’Ulm
Publications
Download-
2019Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine., Brain Behav Immun. 2019 Jun 28.
-
2015Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale, J. Psychopharmacol. (Oxford) 2015 Aug;.
-
2015Is Polyuria a Predictive Sign of Lithium Response in Major Depression?, J Clin Psychopharmacol 2015 Aug;35(4):471-2.
-
2015Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade, Mol. Psychiatry 2015 Jun;.
-
2015[The legacy of Jean Delay in psychiatry], Encephale 2015 Apr;41(2):105-7.
-
2015[Acute hallucinatory psychosis], Rev Prat 2015 Feb;65(2):223-7.
-
2014Selective augmentation of striatal functional connectivity following NMDA receptor antagonism: implications for psychosis, Neuropsychopharmacology 2015 Feb;40(3):622-31.
-
2014Cognitive remediation therapy (CRT) benefits more to patients with schizophrenia with low initial memory performances, Disabil Rehabil 2015;37(10):846-53.
-
2014Reversible cerebral vasoconstriction syndrome and treatment with monoamine oxidase inhibitor, Aust N Z J Psychiatry 2014 Jul;48(7):684-5.
-
2014Neuropsychological features of adult mastocytosis, Immunol Allergy Clin North Am 2014 May;34(2):407-22.
-
+View full list of publications